Testosterone MDL Judge: Reference Listed Drug Claims Are Preempted

(November 11, 2015, 10:56 AM EST) -- CHICAGO — Although two generic testosterone replacement therapy products are reference listed drugs (RLDs), their manufacturers still cannot add new warnings and claims by plaintiffs in a multidistrict litigation are preempted by federal law, an Illinois federal judge ruled Nov. 9 (In Re: Testosterone Replacement Therapy Products Liability Litigation, No. 14-1748, N.D. Ill.; 2015 U.S. Dist. LEXIS 151414).

(Testosterone opinion available. Document #28-151112-017Z.)

Pfizer Inc. and subsidiary Pharmacia & Upjohn Co. LLC (Pfizer) and Auxilium Pharmaceuticals Inc. are among eight defendants in the testosterone replacement therapy...
To view the full article, register now.